Literature DB >> 30628015

The complexity of an overlap type resistant cryoglobulinemia: a case report and review of the literature.

Milena Tocut1, Ziv Rozman2, Alexander Biro3, Asher Winder4,5, Amir Tanay5,6, Gisele Zandman-Goddard7,8.   

Abstract

Type I cryoglobulinemia is associated with B cell proliferative diseases, whereas essential mixed cryoglobulinemia is classically associated with infections, malignancy, and autoimmune diseases, but may be idiopathic. Prognosis in patients with grave manifestations and renal involvement is often poor. We report a case of a 40-year-old woman, 2 weeks post-partum for pre-eclampsia who was hospitalized with nephritic syndrome and acute renal failure. The patient harbored type I and type II cryoglobulinemia. Renal and cutaneous biopsies confirmed the diagnosis; however, an underlying etiology was not established. A bone marrow biopsy suggested monoclonal gammopathy of undetermined source (MGUS). Despite therapy with intravenous cyclophosphamide, rituximab, plasmapheresis, dialysis, and bortezomib, the patient succumbed after 8 months of hospitalization. We suggest that an overlap entity of types I and II cryoglobulinemia with severe multi-organ involvement not only is rare but also may be resistant to conventional therapy and fatal.

Entities:  

Keywords:  Bortezomib; Cryoglobulinemia type I; Cyclophosphamide (CYC); Mixed cryoglobulinemia; Monoclonal gammopathy of unclear significance (MGUS); Plasma exchange; Rituximab (RTX); Vasculitis

Mesh:

Substances:

Year:  2019        PMID: 30628015     DOI: 10.1007/s10067-018-04423-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey.

Authors:  Benjamin Terrier; Evguenia Krastinova; Isabelle Marie; David Launay; Adeline Lacraz; Pauline Belenotti; Luc de Saint-Martin; Thomas Quemeneur; Antoine Huart; Fabrice Bonnet; Guillaume Le Guenno; Jean-Emmanuel Kahn; Olivier Hinschberger; Patricia Rullier; Elisabeth Diot; Estibaliz Lazaro; Frank Bridoux; Thierry Zénone; Fabrice Carrat; Olivier Hermine; Jean-Marc Léger; Xavier Mariette; Patricia Senet; Emmanuelle Plaisier; Patrice Cacoub
Journal:  Blood       Date:  2012-04-03       Impact factor: 22.113

Review 2.  Cryoglobulinemia Vasculitis.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; David Saadoun
Journal:  Am J Med       Date:  2015-03-30       Impact factor: 4.965

3.  Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review.

Authors:  Marcella Visentini; Carmine Tinelli; Stefania Colantuono; Monica Monti; Serena Ludovisi; Laura Gragnani; Milica Mitrevski; Jessica Ranieri; Elisa Fognani; Alessia Piluso; Massimo Granata; Annalisa De Silvestri; Valeria Scotti; Mario U Mondelli; Anna Linda Zignego; Massimo Fiorilli; Milvia Casato
Journal:  Autoimmun Rev       Date:  2015-05-29       Impact factor: 9.754

Review 4.  Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach.

Authors:  Rodolfo Perez-Alamino; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

Review 5.  How I treat cryoglobulinemia.

Authors:  Eli Muchtar; Hila Magen; Morie A Gertz
Journal:  Blood       Date:  2016-10-31       Impact factor: 22.113

6.  Mixed IgG-IgM cryoglobulinemia with glomerulonephritis. Immunochemical, fluorescent and ultrastructural study of kidney and in vitro cryoprecipitate.

Authors:  D Cordonnier; H Martin; P Groslambert; C Micouin; F Chenais; P Stoebner
Journal:  Am J Med       Date:  1975-12       Impact factor: 4.965

7.  Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.

Authors:  Stefania Colantuono; Milica Mitrevski; Baoran Yang; Julia Tola; Maurizio Carlesimo; Giuseppe M De Sanctis; Massimo Fiorilli; Milvia Casato; Marcella Visentini
Journal:  Clin Rheumatol       Date:  2017-01-22       Impact factor: 2.980

8.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido Ed; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2002-08

Review 9.  The diagnosis and classification of the cryoglobulinemic syndrome.

Authors:  Jan Damoiseaux
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

10.  Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey.

Authors:  Benjamin Terrier; Fabrice Carrat; Evguenia Krastinova; Isabelle Marie; David Launay; Adeline Lacraz; Pauline Belenotti; Luc de Saint Martin; Thomas Quemeneur; Antoine Huart; Fabrice Bonnet; Guillaume Le Guenno; Jean-Emmanuel Kahn; Olivier Hinschberger; Patricia Rullier; Aurelie Hummel; Elisabeth Diot; Christian Pagnoux; Estibaliz Lzaro; Frank Bridoux; Thierry Zenone; Olivier Hermine; Jean-Marc Leger; Xavier Mariette; Patricia Senet; Emmanuelle Plaisier; Patrice Cacoub
Journal:  Ann Rheum Dis       Date:  2012-05-14       Impact factor: 19.103

View more
  1 in total

1.  Autoimmune Disease Classification Based on PubMed Text Mining.

Authors:  Hadas Samuels; Malki Malov; Trishna Saha Detroja; Karin Ben Zaken; Naamah Bloch; Meital Gal-Tanamy; Orly Avni; Baruh Polis; Abraham O Samson
Journal:  J Clin Med       Date:  2022-07-26       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.